The Relationship Between Firm Resilience to Supply Chain Disruptions and Firm Innovation

ThisFirm resiliencechapter discusses theSupply chain disruptions relationship betweenInnovationsupply chainSupply chaindisruption risk managementDisruption risk management and innovationInnovation management and examines whether a firm’s investment in innovationInnovation can improve the firm’s resilienceResilience to supply chainSupply chain disruption. We review the antecedents of both firm innovativeness and firm resilienceFirm resilience to supply chain disruptionsSupply chain disruptions, and we identify how investment in innovationInnovation can enhance a firm’s response to supply chain disruptionsSupply chain disruptions using a systematic literature review process. We identify leadershipLeadership, information sharing, and collaboration as practices that improve both firm innovationInnovation and firm resilienceFirm resilience to supply chainSupply chain disruption. We discuss future research directions to further examine the relationship between a firm’s innovationInnovation capability and the firm’s resilienceResilience to supply chain disruptionsSupply chain disruptions

Chemokine receptor oligomerization to tweak chemotactic responses

Chemokine receptors guide cell migration by responding to local chemokine gradients during immune surveillance and inflammation. Similar to other G protein-coupled receptors, chemokine receptors can form oligomeric complexes that might have distinct pharmacological and biochemical properties as compared to their individual constituents. The majority of evidence for chemokine receptor oligomers came from transfected cells using tagged receptors to monitor their close proximity or physical association. However, translation of these observations to (patho)-physiological consequences is puzzling for the majority of chemokine receptor oligomers due to experimental limitations and challenges to distinguish oligomer- from downstream signaling-mediated crosstalk. Recent methodological advances allow in situ validation of chemokine receptor oligomers in native cells, disruption of oligomers, and detection of oligomer-mediated signaling. Chemokine receptor oligomerization modulates cell migration in (patho)-physiology and consequently offers novel therapeutic targets